5. Roberts KG, Reshmi SC, Harvey RC, et al. Genomic and outcome analyses of Ph-like ALL in NCI
standard-risk patients: a report from the Children's Oncology Group. Blood. 2018:blood-2018-2004-
841676.
6. Herold T, Schneider S, Metzeler KH, et al. Adults with Philadelphia chromosome-like acute
lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual
disease and poor prognosis. Haematologica. 2017;102(1):130-138.
7. Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in
adults. Blood. 2017;129(5):572-581.
8. Tasian SK, Hurtz C, Wertheim GB, et al. High incidence of Philadelphia chromosome-like acute
lymphoblastic leukemia in older adults with B-ALL. Leukemia. 2017;31(4):981-984.
9. Roberts KG, Gu Z, Payne-Turner D, et al. High Frequency and Poor Outcome of Philadelphia
Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol. 2017;35(4):394-401.
10. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk
B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide
DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116(23):4874-
4884.
11. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia.
Blood. 2017;130(19):2064-2072.
12. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic
leukemia. N Engl J Med. 2009;360(5):470-480.
13. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1(plus) Defines a New Minimal Residual Disease-
Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J
Clin Oncol. 2018;36(12):1240-1249.
14. Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of
Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17):3510-3518.
15. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor
signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153-166.
16. Iacobucci I, Li Y, Roberts KG, et al. Truncating Erythropoietin Receptor Rearrangements in Acute
Lymphoblastic Leukemia. Cancer Cell. 2016;29(2):186-200.
17. Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL
inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2017;129(2):177-
187.
18. Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like
acute lymphoblastic leukemia. Blood Adv. 2020;4(1):218-228.